Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics (Nasdaq:PTGX) granted equity inducement awards to three new employees on June 15, 2026, under its Amended and Restated Inducement Plan.

Rhea-AI Summary

Protagonist Therapeutics (Nasdaq:PTGX) granted equity inducement awards to three new employees on June 15, 2026, under its Amended and Restated Inducement Plan.

The grants total 14,800 stock options at a $112.46 exercise price and 3,900 RSUs, with four-year vesting schedules, approved under Nasdaq Rule 5635(c)(4).

Argus Jun 17 session

+0.72% close to close Open Argus

Details

News Market Reaction – PTGX

On Jun 17, the first trading day after this news, PTGX closed 0.72% above the previous close.

Data tracked by StockTitan Argus for the Jun 17 session.

Key Figures

Current share price: $112.46 Stock options granted: 14,800 shares RSUs granted: 3,900 shares +5 more

Current share price

$112.46

Nasdaq Global Market close on June 15, 2026

Stock options granted

14,800 shares

Inducement awards to three new employees on June 15, 2026

RSUs granted

3,900 shares

Inducement awards to three new employees on June 15, 2026

Option exercise price

$112.46

Equal to PTGX closing price on June 15, 2026

Option vesting period

4 years

25% at first anniversary, remainder monthly over next 3 years

RSU vesting schedule

4 years

One-fourth of RSU shares vest annually

New hires covered

3 employees

Recently hired employees receiving inducement awards

Inducement plan adoption

May 29, 2018

Plan later amended Feb 18, 2020 and Feb 15, 2022

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   Clinical data presentations

   24h Move

   -4.7%

   Phase 3 VERIFY and long-term rusfertide data slated for EHA Congress.

2. May 28

   Conference participation

   24h Move

   -1.8%

   CEO scheduled for fireside chats at two June healthcare conferences.

3. May 05

   Earnings and update

   24h Move

   +4.8%

   Q1 2026 results with ICOTYDE approval and strong rusfertide economics.

4. Apr 28

   Collaboration opt-out

   24h Move

   +2.7%

   Rusfertide U.S. opt-out under Takeda deal, unlocking major milestone potential.

5. Apr 16

   Inducement awards

   24h Move

   +2.2%

   Stock options and RSUs granted to new hires under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units (rsus), nasdaq global market, inducement plan

3 terms

restricted stock units (rsus) financial

"options to purchase 14,800 shares ... and restricted stock units (RSUs) to acquire 3,900 shares"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

nasdaq global market regulatory

"equal to the per-share closing price ... on the Nasdaq Global Market on June 15, 2026"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

inducement plan financial

"granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 14,800 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,900 shares of Protagonist Therapeutics common stock. The exercise price of the options is $112.46, which is equal to the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on June 15, 2026. The shares subject to each option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of each employee's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to each employee entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Protagonist Therapeutics (PTGX) grant on June 15, 2026?

Protagonist Therapeutics granted stock options for 14,800 shares and 3,900 RSUs to three new employees. According to the company, these awards were issued under its Amended and Restated Inducement Plan as a material employment inducement.

What is the exercise price of the June 2026 Protagonist Therapeutics (PTGX) stock options?

The stock options have an exercise price of $112.46 per share. According to Protagonist Therapeutics, this equals the closing price of its common stock on the Nasdaq Global Market on June 15, 2026.

How do the Protagonist Therapeutics (PTGX) inducement stock options vest for new employees?

The options vest over four years, with 25% vesting on the first anniversary of each hire date. According to Protagonist Therapeutics, the remaining 75% vest in equal monthly installments over the following three years.

What is the vesting schedule for the Protagonist Therapeutics (PTGX) RSU inducement grants?

The RSUs vest over a four-year period, with one-fourth of the shares vesting each year. According to Protagonist Therapeutics, this annual vesting continues until all 3,900 RSU shares are fully vested.

Under which plan were the June 2026 Protagonist Therapeutics (PTGX) inducement awards granted?

The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan. According to the company, this plan was adopted May 29, 2018 and amended in 2020 and 2022.

How does Nasdaq Rule 5635(c)(4) relate to Protagonist Therapeutics (PTGX) inducement awards?

The awards were approved as material inducements to employment under Nasdaq Rule 5635(c)(4). According to Protagonist Therapeutics, the compensation committee of its board approved these grants consistent with that rule.